Treatment of ragweed hay fever with flurbiprofen, a cyclooxygenase-inhibiting drug.
Sixty-two volunteer hay fever patients participated in a 2-week trial which examined the protective effect of the cyclooxygenase-inhibiting drug flurbiprofen. The drug suppressed symptom severity significantly, though it was not as protective as the antihistamine also employed in the trial. Flurbiprofen's effects suggests that prostaglandin release may contribute to the symptoms of allergic rhinitis.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors; D005260:Female; D005480:Flurbiprofen / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009297:Nasal Mucosa / Q000378:metabolism; D011058:Pollen; D011422:Propionates / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy; D011897:Random Allocation; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012912:Sneezing / Q000187:drug effects
D016861:Cyclooxygenase Inhibitors; D011422:Propionates; D005480:Flurbiprofen